000078 ST海王生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入5,945,149-19.39%26,667,70930,317,28836,418,77037,834,859
减:营业总成本5,931,657-19.33%26,741,85230,630,05836,503,98437,782,459
    其中:营业成本5,393,652-19.43%24,209,62327,444,70732,865,44534,045,035
               财务费用107,861-28.25%613,669806,282943,621905,212
               资产减值损失(6,126)-306.50%(126,427)(518,749)(962,355)(550,406)
公允价值变动收益2,45110,222.07%11,9956,38417,75256,847
投资收益(23,241)-124.39%8,92111,147(45,418)(143,505)
    其中:对联营企业和合营企业的投资收益(1,051)-11,581.11%5,8694,318(26,996)(106,917)
营业利润45,761-48.76%(504,929)(1,062,938)(1,468,030)(854,588)
利润总额46,081-49.23%(499,300)(1,081,694)(1,458,474)(853,160)
减:所得税费用21,009-44.42%53,25685,617260,559138,290
净利润25,072-52.65%(552,556)(1,167,311)(1,719,033)(991,450)
减:非控股权益10,580-63.82%10,50426,104(29,088)35,519
股东净利润14,492-38.89%(563,060)(1,193,415)(1,689,945)(1,026,969)

市场价值指针
每股收益 (元) *0.006-38.89%-0.214-0.454-0.642-0.391
每股派息 (元) *------------
每股净资产 (元) *0.472-31.74%0.4660.6821.0921.705
审计意见 #--保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容